DDInter842 DDInter1628
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Fludarabine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Fludarabine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluorouracil
Fluorouracil {u} (Compound) binds {v} (Gene) UMPS
UMPS {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) downregulates {v} (Gene) TCERG1
TCERG1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clofarabine
Clofarabine {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) downregulates {v} (Gene) C2CD5
C2CD5 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) upregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine and Fludarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine and Fludarabine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fluorouracil and Fluorouracil (Compound) binds UMPS (Gene) and UMPS (Gene) is upregulated by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) downregulates TCERG1 (Gene) and TCERG1 (Gene) is upregulated by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine and Clofarabine (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) downregulates C2CD5 (Gene) and C2CD5 (Gene) is downregulated by Ruxolitinib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) upregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Ruxolitinib (Compound)